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Abstract
Multidrug-resistant Gram-positive infections remain a signiﬁcant therapeutic problem, especially those due to Staphylococcus aureus. Anti-
microbial choice is only one aspect of the management of these infections. New immunotherapies, exploitation of novel antibiotic tar-
gets, topical therapies and new drug delivery systems may have a future role in the management of S. aureus infection. At present,
injectable antimicrobials are the main area of drug development and clinical interest. Since 1999, ﬁve anti-Gram-positive agents (moxi-
ﬂoxacin, quinupristin–dalfopristin, linezolid, daptomycin and tigecycline) have become available in the EU. At present, three other anti-
Gram-positive agents are being considered by the European Medicines Agency (ceftobiprole, gemiﬂoxacin and iclaprim), and a further
four have completed phase III clinical trials (ceftaroline, dalbavancin, oritavancin and telavancin). The antibacterial spectra of these
agents, their in vitro potencies, bactericidal activities and pharmacokinetics are well known. The safety proﬁles for those agents that have
received regulatory approval and entered clinical practice are also ﬁrmly established. Most of the agents are pharmacodynamically prom-
ising and effective in clinical trials. As in the past, drug safety is likely to be a major determinant of which of the most recent drugs
receive regulatory approval, and, in the long term, which agents will be successful in clinical practice.
Keywords: Bacteraemia, Gram-positive infections, Staphylococcus aureus, therapeutic options
Clin Microbiol Infect 2009; 15 (Suppl. 6): 17–25
Corresponding author and reprint requests: A. MacGowan,
Bristol Centre for Antimicrobial Research & Evaluation, University of
Bristol and North Bristol NHS Trust, Department of Medical Micro-
biology, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB,
UK
E-mail: alasdair.macgowan@nbt.nhs.uk
This article forms part of a supplement based on the proceedings of
a Novartis-sponsored symposium at the 18th European Congress of
Clinical Microbiology and Infectious Diseases (ECCMID), April 2008,
entitled ‘Positive outcomes in Gram-positive infections.’ The supple-
ment is supported by an educational grant for production and distri-
bution from Novartis, with editorial and writing support provided by
Chameleon Communications International with Novartis Pharma AG
sponsorship.
Introduction
In the past decade, a number of new antibacterial agents
have become available for clinical use to meet the chal-
lenges surrounding the clinical management of Gram-positive
infections. These agents have been aimed at the therapy of
infections caused by multidrug-resistant Streptococcus pneumo-
niae and Staphylococcus aureus, and by vancomycin-resistant
enterococci. In this short review, we focus mainly on issues
pertaining to the management of S. aureus infections, of
which the most serious is bacteraemia or bloodstream infec-
tion.
There are a number of important, unresolved clinical
questions surrounding the management of S. aureus bactera-
emia, including some that are independent of the choice of
antimicrobial agent (Table 1). In addition, there is ongoing
interest in the use of topical therapies and immunotherapies
for S. aureus infections, and novel targets and new antibiotic
delivery systems are currently under investigation. However,
the main focus of drug development and clinical interest has
revolved around a number of new injectable antimicrobials
developed to treat infections caused by methicillin-resistant
S. aureus (MRSA) and other multidrug-resistant Gram-posi-
tive organisms.
Immunotherapy
Intravenous immunoglobulin has been recommended in the
UK for selected patients with infection due to necrotizing
(associated with Panton–Valentine leukocidin) staphylococcal
sepsis, staphylococcal toxic shock syndrome and severe
group A streptococcal infection [1]. A recent randomized,
double-blind, placebo-controlled phase II trial of a polyclonal
anti-S. aureus capsular polysaccharide immunoglobulin in 40
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patients with S. aureus bacteraemia indicated a trend towards
a shorter duration of fever in those receiving standard
therapy plus immunoglobulin (n = 21) as compared with those
receiving standard therapy and placebo, and also a shorter
duration of hospital stay [2]. Although the study was not
powered to show efﬁcacy, these data are at least promising
in terms of future antibody therapies in S. aureus infection.
Novel Targets
Small, acid-soluble proteins (SASPs) comprise a small group
of proteins that bind to and inactivate bacterial DNA. SASP
genes can be delivered to S. aureus via an S. aureus-speciﬁc
delivery bacteriophage, resulting in the production of SASPs
in these targeted bacteria. These proteins have been shown
to be active against a range of S. aureus strains and to be
rapidly bactericidal, irrespective of existing antibiotic resis-
tances [3–5].
In addition, a number of antimicrobial peptides with anti-
staphylococcal activity have been described, such as the fol-
lowing: NZ2114, which is derived from plectasin, a defensin-
type peptide [6,7]; MU 1140, a lantibiotic (lanthionine-con-
taining peptide antibiotic) [8]; and RTA-3, a 16 amino acid
peptide derived from Streptococcus mitis [9]. A further, struc-
turally distinct group of molecules—membrane-active dicat-
ionic porphyrins—is also being developed for topical and
systemic therapy for S. aureus infections [10].
Topical Therapies and New Antibiotic
Delivery Systems
Retapamulin is a topical antibiotic and the ﬁrst pleuromutilin
to be approved for clinical use in humans. Both the US Food
and Drug Administration and the European Medicines
Agency (EMEA) approved its use in bacterial skin infections
in 2007 [11,12]. Five days of topical therapy have been
shown to be superior to placebo in impetigo [13], non-infe-
rior to topical fusidic acid in impetigo [14] and non-inferior
to oral cephalexin in secondary infected traumatic lesions
and infected dermatoses [15,16]. As such, it may represent a
topical alternative to oral therapy, reducing the use of estab-
lished oral anti-Gram-positive agents.
Aerosolization systems such as BAY41-6551 (a drug
device combination for inhaled amikacin) are in phase II
development as methods of delivering adjunctive therapy to
ventilated patients with pneumonia [17]. Although primarily
intended to improve outcomes in patients with Gram-nega-
tive infections, they may also have a role in Gram-positive
infections [18].
A Decade of Injectable Anti-Gram-positive
Antimicrobials
Five injectable anti-Gram-positive agents have become avail-
able for clinical use in most EU countries since 1999
(Table 2). In mid-2008, a further ﬁve drugs were under con-
sideration by the EMEA (Table 3) and, at present, two of
these have been withdrawn from the regulatory process
(dalbavancin and telavancin) [19,20]. This is pending a further
clinical trial (dalbavancin) and completion of data analysis
from ﬁnished trials (telavancin) [19,20]. At present, it is
expected that both agents will be resubmitted once the addi-
tional data are analysed or generated.
TABLE 1. Unresolved management issues in the
antimicrobial treatment of serious Staphylococcus aureus
infections
Duration of intravenous therapy and total duration of therapy
Role of oral therapy
Monotherapy vs. combination therapy
Need for chosen antibiotics to have bactericidal action
Timing of appropriate therapy and impact of disease severity
Role of rapid diagnosis or MRSA screening
Use of glycopeptides as initial therapy
Second-line therapy after glycopeptide failure: addition of or switch to other agents
Glycopeptide ﬁ glycopeptide, or
Glycopeptide ﬁ daptomycin or linezolid, or
Glycopeptide ﬁ b-lactam
MRSA, methicillin-resistant S. aureus.
TABLE 2. Anti-Gram-positive agents that have received
marketing authorization from the European Medicines
Agency since 1999 [21–25]
Agent (pharmaceutical
company) Drug class
First
approval
date for any
indication
All indications
to date in
Europe
Moxiﬂoxacin
(Bayer HealthCare) [21]
Fluoroquinolone 1999 CAP, acute
exacerbation
of chronic
bronchitis, acute
sinusitis
Quinupristin–dalfopristin
(Nordic Pharma)a [22]
Streptogramin 1999 cSSTI, NP,
VREF infections
Linezolid (Pﬁzer)a [23] Oxazolidinone 2000 cSSTI, CAP, NP
Daptomycin (Novartis
Pharmaceuticals) [24]
Cyclic lipopeptide 2005 cSSTI, RIE due to
Staphylococcus aureus,
SAB associated
with RIE or cSSTI
Tigecycline (Wyeth) [25] Glycylcycline 2005 cSSTI, cIAI
CAP, community-acquired pneumonia; cIAI, complicated intra-abdominal infec-
tion; cSSTI, complicated skin and soft tissue infection; NP, nosocomial pneumo-
nia; RIE, right-sided infective endocarditis; SAB, S. aureus bacteraemia; VREF,
vancomycin-resistant Enterococcus faecium.
aMarketing authorization holders in Europe: quinupristin–dalfopristin, Monarch
Pharmaceuticals Ireland Ltd [22]; linezolid, Pharmacia Ltd [23].
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The anti-Gram-positive agents approved recently in Eur-
ope are listed in Table 2 [21–25]. Moxiﬂoxacin has marketing
authorization in some parts of the world for complicated
skin and soft tissue infections [26], as well as for respiratory
indications in Europe [27]. However, the beneﬁt–risk balance
of the oral formulation has been reviewed recently by the
EMEA after a safety review by the German medicines regula-
tory authority, which indicated that eight patients had suf-
fered liver problems that led to death, suspected to be
related to moxiﬂoxacin [27]. The use of oral moxiﬂoxacin is
now limited to treatment where other antibiotics cannot be
used or, with respect to acute bacterial sinusitis and acute
exacerbation of chronic bronchitis, have stopped working
[27]. In addition, recent data from the USA indicate that the
rate of emergency room visits for adverse events may be
higher for moxiﬂoxacin than for other ﬂuoroquinolones [28].
Quinupristin–dalfopristin has been available since 1999, but
its use is limited by a number of factors, including lack of
activity against Enterococcus faecalis, cost and adverse events,
such as inﬂammation, pain, oedema, thrombophlebitis, injec-
tion site reactions when given by peripheral administration,
myalgia or arthralgia, and the need to administer via a central
venous line [29,30]. In addition, quinupristin–dalfopristin has
not demonstrated superiority to vancomycin or b-lactams in
clinical trials [30]. In April 2008, Wyeth withdrew its applica-
tion to extend marketing authorization for tigecycline to
community-acquired pneumonia (CAP) [31]. This was based
on the EMEA’s opinion that the submitted data did not
support a positive beneﬁt–risk balance for CAP [31].
The unlicensed anti-Gram-positive agents that have com-
pleted phase III clinical trials or are at present under consid-
eration by the EMEA are shown in Table 3. A number of
newer agents are in early clinical development and have
completed, or are undergoing, phase II clinical trials in
Gram-positive infections. These are shown in Table 4 [17,
32–35].
The in vitro potencies of these newer anti-Gram-positive
agents, together with those of vancomycin and teicoplanin,
are shown in Table 5 [36–57]. Most agents are equipotent
against methicillin-susceptible S. aureus and MRSA, except for
the b-lactams ceftobiprole [42] and ceftaroline [50], which
are more potent against methicillin-susceptible S. aureus than
MRSA. Glycopeptides and daptomycin have reduced potency
against vancomycin-intermediate S. aureus and heterogeneous
vancomycin-intermediate S. aureus strains [38]. All of the
lipoglycopeptides (dalbavancin, oritavancin and telavancin)
have reduced activity in vitro against vancomycin-resistant
enterococci as compared with vancomycin-susceptible
enterococci [41,46,54], and ceftobiprole, ceftaroline, dapto-
mycin and iclaprim have reduced potency against Enterococcus
faecium in comparison with E. faecalis [36,49,50,53]. All of
the agents have good or acceptable potency against S. pneu-
moniae but, for the anti-MRSA cephalosporins, the MICs are
related to the level of penicillin resistance [49,50]. As well as
being active against Gram-positive bacteria, some of these
agents also have in vitro activity against aerobic Gram-nega-
tive rods and/or anaerobes such as Bacteroides fragilis
(Table 6). This increased spectrum means that a wider range
of clinical conditions can be treated with some agents as
monotherapy, but may bring disadvantages, such as an
increased risk of Clostridium difﬁcile-associated diarrhoea.
TABLE 4. Anti-Gram-positive agents that have completed
phase II trials or for which phase II trials are ongoing
[17,32–35]
Agent (pharmaceutical
company) Class Indications
BAY41-6551 (Nektar Therapeutics/
Bayer HealthCare) [17]
Aminoglycoside/
new delivery system
Gram-negative
pneumonia in
mechanically
ventilated patients
PTK 0796 (Paratek
Pharmaceuticals) [33]
Aminomethylcycline cSSTI
PZ-601 (Novartis Pharmaceuticals)
[34]
Carbapenem cSSTI
Radezolid (Rib-X Pharmaceuticals)
[35]
Oxazolidinone CAP, uSSTI
Tomopenem (Daiichi Sankyo) [32] Carbapenem cSSTI
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue
infection; uSSTI, uncomplicated skin and soft tissue infection.
TABLE 3. Anti-Gram-positive agents without European
Medicines Agency (EMEA) marketing authorization that
have completed phase III trials or are under consideration
by the EMEA
Agent (pharmaceutical
company) Class
Marketing
authorization
application
under review
by the EMEA
Indications
for which
phase III trials
are completed
Ceftobiprole (Janssen-Cilag) Cephalosporin Yes cSSTI, NP
Ceftaroline (Forest
Laboratories)
Cephalosporin No cSSTI
Dalbavancin (Pﬁzer) Lipoglycopeptide Noa cSSTI
Gemiﬂoxacin (the
Menarini Group)
Fluoroquinolone Yes CAP, acute
exacerbation of
chronic bronchitis
Iclaprim (Arpida Ltd) Diaminopyrimidine Yes cSSTI
Oritavancin (Targanta
Therapeutics)
Lipoglycopeptide No cSSTI
Telavancin (Astellas
Pharma Europe)
Lipoglycopeptide Nob cSSTI, HAP
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue
infection; EMEA, European Medicines Agency; HAP, hospital-acquired pneumo-
nia; NP, nosocomial pneumonia.
aWithdrawn from consideration by the EMEA on 10 September 2008 [19].
bWithdrawn from consideration by the EMEA on 24 October 2008 [20].
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Bactericidal activity is an important microbiological charac-
teristic of an antibacterial agent. However, its clinical impor-
tance is often difﬁcult to judge, except in the context of
infective endocarditis and in some severely immunocompro-
mised patients. Comparisons of the bactericidal activity of
different drugs are also difﬁcult, and the degree of killing
depends on bacterial species, and sometimes even the strain,
the concentration of drug used, and the duration over which
performance is assessed. However, assuming that a strain of
S. aureus is susceptible to the agent, oxazolidinones and tet-
racyclines are relatively bacteriostatic, whereas aminoglyco-
sides, b-lactams and daptomycin are the most bactericidal.
Glycopeptides occupy an intermediate position, with the
degree of killing being dependent on bacterial inoculum,
duration of drug exposure and the strain tested [58].
The pharmacokinetic properties of different agents are
shown in Table 7 [59–68]. Of note are the long serum half-
lives of dalbavancin and oritavancin, which make these agents
suitable for very infrequent dosing, such as two or three times
a week or once a week (dalbavancin) [59]. The volume of dis-
tribution of tigecycline is very large, c. 500 L, indicating consid-
erable concentration in some tissues [69,70]. With the
exception of the b-lactam agents (ceftobiprole and ceftaro-
line), many of these drugs are highly protein-bound; however,
their clinical antimicrobial effect is determined by a combina-
tion of their antibacterial potency, pharmacodynamics and
pharmacokinetics.
The warnings and precautions, and adverse event pro-
ﬁles, of the three most recently marketed agents as
extracted from European Summary of Product Characteris-
tics, are shown in Tables 8 and 9, respectively [23–25].
With daptomycin, the main safety concerns surround
increases in creatine phosphokinase level, muscle pain,
myopathy and, most seriously, rhabdomyolysis; peripheral
neuropathy has also been reported [24]. With linezolid, the
main clinical concerns are myelosuppression (anaemia, neu-
tropenia and thrombocytopenia), peripheral/optic neuropa-
thy and lactic acidosis [23]. With tigecycline, there are a
range of tetracycline class effects, and nausea and vomiting,T
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TABLE 6. Antibacterial spectrum of both marketed and
non-licensed antimicrobial agents
Gram-positive
spectrum only
Gram-positive
and aerobic
Gram-negative rods
Gram-positive,
Gram-negative and
Bacteroides fragilis
Dalbavancin Ceftaroline Moxiﬂoxacin
Daptomycin Ceftobiprole PZ-601
Linezolid Iclaprim PTK 0795
Oritavancin Gemiﬂoxacin Tigecycline
Quinupristin–dalfopristin Tomopenem
Telavancin
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which occur in up to 20% of subjects (Table 9); acute
pancreatitis occurs uncommonly [25]. Daptomycin is not
effective in CAP [71], and the efﬁcacy and safety of tigecy-
cline have not been fully established in nosocomial pneumo-
nia, owing to its poor performance in patients with
ventilator-associated pneumonia [72]. The safety proﬁles of
the new agents not yet approved in the USA or Europe
have not been described fully.
A summary of the hospital formulary alternatives for the
therapy of Gram-positive infections in skin, blood and lungs
is shown in Table 10 [19–26,71–73]. The approved indica-
tions listed include those approved in Europe or in the USA,
but not necessarily in both. Moxiﬂoxacin, for example, is not
licensed for use in complicated skin and soft tissue infections
or complicated intra-abdominal infections in Europe as it is
in the USA [21,26].
Ceftobiprole recently met the assigned non-inferiority cri-
teria as compared with ceftazidime combined with linezolid
TABLE 7. Pharmacokinetics of anti-Gram-positive agents [59–68]
Agent Dose studieda Cmax (mg/L) AUC0–24 (mg/L/h) t1/2 (h) VD (L/kg) Free fraction
Vancomycin [59] 1 g or 15 mg/kg every 12 h 20–50 520 4–8 0.3 0.45–0.9
Teicoplanin [59] 400 mg or 6 mg/kg every 24 h 40–45 550 83–168 0.9–1.6 0.1
Ceftobiprole [60] 500 mg every 12 h 44 102b 4.0 17c 0.84
750 mg every 12 h 61 156b 4.1 16c 0.88
Ceftaroline [66] 600 mg (single dose) 19.7 44.6b 2.1 – >0.8
Dalbavancin [59] 15 mg/kg or 1 g for 7 days 300 23 250d 257 0.16 0.02
Daptomycin [61] 4 mg/kg every 24 h 58 494 8.1 0.1 0.1
6 mg/kg every 24 h 99 747 8.9 0.1
8 mg/kg every 24 h 133 1130 9.0 0.1
Iclaprim [67] 60 mg every 12 h 1.5 1.5d 1.6 92.4c 0.07
120 mg every 12 h 3.0 3.4d 1.9 96.4c
Linezolid [62] 600 mg every 12 h, oral 21 276 5.4 30–50c 0.69
Oritavancin [59,68] 3 mg/kg every 24 h 31 152 360 0.65–1.92 0.1
Telavancin [63,65] 15 mg/kg every 24 h 186 1282 7.5 0.1 0.07
Tigecycline [64] 50 mg every 12 h 0.6 3.0 37 7.2 0.13–0.29
100 mg every 12 h 1.1 5.0 66 9.1
AUC0–24, area under the concentration–time curve between 0 h and 24 h; Cmax, maximum serum concentration; t1/2, plasma half-life; VD, volume of distribution.
aMay be different from the licensed dose.
bAUC0–12 (mg/L/h).
cVD (L).
dAUC0–¥ (mg/L/h).
TABLE 8. Warnings and precautions in the European
Summary of Product Characteristics for daptomycin,
linezolid and tigecycline [23–25]
Agent Warnings and precautions
Daptomycin [24] Consider using another agent
if SAB is not related to RIE or cSSTI
Not effective in pneumonia
Efﬁcacy not demonstrated in left-sided
endocarditis or prosthetic valve infective endocarditis
Raised CPK levels (myopathy, muscle
pain, weakness, rhabdomyolysis)
Peripheral neuropathy
Link to myopathy in renal insufﬁciency
Linezolid [23] Myelosuppression (anaemia, neutropenia,
thrombocytopenia, pancytopenia)
Imbalance in outcomes in a study of patients with
intravenous catheter-related BSI, including catheter
site infection (not seen in those infected
with Gram-positive bacteria)
Lactic acidosis
Serotonin syndrome
Peripheral/optic neuropathy,
visual impairment
Convulsions
Tigecycline [25] Potentially life-threatening
anaphylactoid reactions
Tetracycline class effects (bone discoloration,
photosensitivity, pseudotumour cerebri,
anti-anabolic action)
Acute pancreatitis
Experience in patients with severe
underlying diseases is limited
Consider a second agent in severely ill patients
with cIAI, clinical perforation, incipient sepsis or shock
Patients presenting with cholestasis
should be closely monitored
Efﬁcacy and safety not established in HAP
BSI, bloodstream infection; cIAI, complicated intra-abdominal infection; CPK,
creatine phosphokinase; cSSTI, complicated skin and soft tissue infection; HAP,
hospital-acquired pneumonia; SAB, Staphylococcus aureus bacteraemia; RIE, right-
sided infective endocarditis.
TABLE 9. Common (1–10%) adverse events with
daptomycin, linezolid and tigecycline as detailed in the
European Summary of Product Characteristics [23–25]
Daptomycin [24] Linezolid [23] Tigecycline [25]
Fungal infections Fungal infections Abscess, infections
Headache
Nausea, vomiting,
diarrhoea
Rash
Infusion site reactions
Abnormal liver
function tests
Increased CPK
Vaginal/oral candidiasis
Headache
Nausea, vomiting,
diarrhoea
Taste alteration
Tongue discoloration
Abnormal liver
function tests
Haematological disturbance
(increased neutrophils/
eosinophils; anaemia)
Prolonged aPTT,
prolonged PT
Dizziness
Phlebitis
Nausea, vomiting,
diarrhoea
Abdominal pain,
dyspepsia, anorexia
Pruritis, rash
Headache
Abnormal liver
function tests
aPTT, activated partial thromboplastin time; CPK, creatine phosphokinase; PT,
prothrombin time.
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in a randomized phase III trial in nosocomial pneumonia, but
signiﬁcantly lower cure rates were observed in ceftobiprole-
treated patients with ventilator-associated pneumonia [74]
(Table 10). Tigecycline, however, failed to meet non-inferior-
ity endpoints in comparison with an imipenem regimen in a
recent randomized phase III trial in hospital-acquired pneu-
monia [72]. The dalbavancin clinical trials were not felt to be
robust enough to justify approval for use in complicated skin
and soft tissue infections by the EMEA, and, most recently,
telavancin was felt to have an adverse efﬁcacy–safety assess-
ment and was withdrawn from the regulatory process
[19,20]. Studies with telavancin in hospital-acquired pneumo-
nia have been conducted and are likely to form the basis of
a resubmission to the regulatory authority for this drug [75].
Summary
There are many unresolved clinical issues in the management
of severe Gram-positive infections, especially those caused
by S. aureus. The choice of the anti-Gram-positive agent is an
important part of management, but only one factor in opti-
mizing patient outcomes. A number of new agents have
become available recently for the treatment of Gram-positive
infections (linezolid, daptomycin and tigecycline), and the
near future will see these agents joined by others (ceftobi-
prole, ceftaroline, dalbavancin, iclaprim, oritavancin and tela-
vancin). These agents are all clinically effective, with
promising pharmacodynamic properties. As in the past, drug
safety is likely to be a major determinant of which drugs
achieve regulatory approval, and also their ultimate success
in clinical practice.
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